Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Simulations Plus Inc(SLP)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SLP
10/07/2026: SLP (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Simulations Plus is a specialized technology company providing modeling and simulation software for pharmaceutical and biotechnology drug development. The company holds a solid position in niche areas like PBPK and pharmacometric modeling, which are critical for optimizing clinical trials and reducing development costs. Its strength lies in its high-margin subscription software and deeply ingrained role in the R&D workflows of major pharmaceutical clients. While the company offers strong growth potential driven by the digitalization of drug R&D, it faces competition from larger firms and risks related to technological shifts. It may suit growth-oriented investors looking for exposure to the biopharma tech sector.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company serves a growing market for computational drug development that benefits from long-term trends in biopharma R&D efficiency. |
| Momentum investor | Mixed fit | Momentum fit is conditional on a positive Upturn signal, reflecting the stock's tendency to react to broader sector sentiment. |
| Value investor | Mixed fit | The stock often trades at premium multiples due to its growth profile, which may limit the margin of safety for strict value investors. |
| Dividend investor | Weak fit | While it pays a dividend, the yield is modest, and the company prioritizes capital reinvestment for growth over high income. |
| Low-risk investor | Weak fit | As a small-cap technology company in the volatile biotechnology space, it carries higher inherent risk than traditional large-cap defensive stocks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | The stock is susceptible to fluctuations in the broader biotech and software sectors. |
| Valuation risk | Medium | It often commands higher valuation multiples, which increases sensitivity to growth rate misses. |
| Competition risk (AI/Big Data competition) | Medium | New AI-native platforms could disrupt traditional simulation modeling if they achieve faster or cheaper results. |
| Business quality | Strong | The company provides high-value, specialized tools that are deeply integrated into client workflows. |
| Dividend income | Low | The dividend is not the primary driver of total returns, making it less suitable for income-focused investors. |
| Execution risk | Medium | Continued success depends on timely R&D updates and effectively managing integration risks from future acquisitions. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -12.5% | Avg. Invested days 43 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/07/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 374.16M USD | Price to earnings Ratio 46.25 | 1Y Target Price 18.5 |
Price to earnings Ratio 46.25 | 1Y Target Price 18.5 | ||
Volume (30-day avg) 220.7K shares | Beta 1.31 | 52 Weeks Range 11.09 - 21.01 | Updated Date 10/25/2026 |
52 Weeks Range 11.09 - 21.01 | Updated Date 10/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.4 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Software Licenses | Annual subscription and maintenance fees for platforms like GastroPlus and MonolixSuite. | This is a high-margin, recurring revenue stream that scales well as more pharmaceutical companies adopt their software. |
| Consulting Services | Contract-based scientific research and simulation services for drug development programs. | This provides steady project-based revenue and deepens client relationships for software cross-selling. |
| Geographic Markets | Global customer base with significant concentrations in North America, Europe, and Asia. | The company benefits from global pharmaceutical R&D spending trends, reducing reliance on any single regional market. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-10-29 | When After Market | Estimate 0.16 | Actual - |
Profitability
Profit Margin 9.88% | Operating Margin (TTM) 22.84% |
Management Effectiveness
Return on Assets (TTM) 5.48% | Return on Equity (TTM) 6.17% |
Valuation
Trailing PE 46.25 | Forward PE 52.91 | Enterprise Value 323.14M | Price to Sales(TTM) 4.56 |
Enterprise Value 323.14M | Price to Sales(TTM) 4.56 | ||
Enterprise Value to Revenue 3.94 | Enterprise Value to EBITDA 18.88 | Shares Outstanding 20.22M | Shares Floating 16.81M |
Shares Outstanding 20.22M | Shares Floating 16.81M | ||
Percent Insiders 16.91 | Percent Institutions 79.23 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.